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PPIs for prevention and treatment of peptic ulcer
The incidence and mortality of peptic ulcer rose markedly 
during the 19th century,1 peaking in the generation 
born at the end of the century, and then steadily 
decreasing. In recent decades, the main ulcer aetiology 
has shifted in many countries from Helicobacter pylori 
to non-steroidal anti-inflammatory drugs (NSAIDs), 
including aspirin. Use of other drugs such as steroids, 
aldosterone antagonists, and selective serotonin 
reuptake inhibitors can contribute to gastroduodenal 
ulceration and its complications.2 This combination 
of factors explains why upper gastro intestinal 
bleeding remains the most common gastro intestinal 
emergency globally. In the USA, gastro intestinal 
bleeding led to 796 000 emergency department 
visits and 435 000 admissions in 2012, comprising 
20% of gastrointestinal emergency admissions that 
year.3 Peptic ulcer is the predominant bleeding source, 
accounting for around 40% of upper gastrointestinal 
bleeds. Many occur in elderly people with comorbidity 
and multidrug use, which, combined with frequent 
presentation with shock, explains why ulcer bleeding 
remains associated with a 5–10% mortality despite 
improvements in management and care. 
This situation calls for primary prevention of ulcer 
formation and ulcer bleeding, improved management 
of a bleed, and prevention of rebleeding. Many studies 
have therefore focused on the effect of gastroprotection, 
in particular by means of proton-pump inhibitors 
(PPIs) as well as histamine-2 receptor antagonists and 
prostaglandin analogues. However, the abundance of 
studies and treatment regimens makes the effects of 
gastroprotection difficult to quantify. 
This challenge underlines the importance of 
the thorough, high-quality systematic review 
and meta-analysis4 of gastroprotectant drug 
trials published in The Lancet Gastroenterology & 
Hepatology. Benjamin Scally and colleagues analysed 
1212 randomised trials of gastroprotectant drugs, 
including 849 trials of 142 485 participants that 
compared a gastroprotectant with control. All included 
trials focused on the effect of gastroprotection on 
peptic ulcer prevention, ulcer healing, and upper 
gastrointestinal bleeding. Scally and colleagues report 
substantial benefits, in particular with PPI treatment, in 
all three areas. Importantly, these effects were of similar 
magnitude in NSAID users and non-users, and did not 
differ between PPIs. PPI treatment was associated 
with an odds ratio of 0·20 (95% CI 0·17–0·23) for 
development of an endoscopic ulcer, of 0·21 (0·12–0·36) 
for an ulcer bleed, and of 5·22 (4·00–6·80) for ulcer 
healing. The comprehensive analysis also allowed an 
investigation of the effects of PPIs on further bleeding 
and complications. PPI treatment significantly reduced 
the risk of further bleeding, and the need for blood 
transfusion, endoscopic intervention, and surgery, 
with ORs ranging between 0·56 and 0·67. Previous 
individual trials have been unable to show any benefit 
of gastroprotection on all-cause mortality in bleeding 
patients, which is confirmed in this systematic review 
(OR 0·90, 95% CI 0·72–1·11).
Scally and colleagues’ findings support guideline 
recommendations for management of patients with 
upper gastrointestinal bleeding, including use of 
intravenous PPIs while awaiting (but not delaying) 
upper endoscopy, oral or intravenous PPIs immediately 
after endoscopy, and oral PPI maintenance in patients 
at high risk for rebleeding.5–7 Do these findings also 
provide definite answers to all clinical issues regarding 
gastroprotectants? The answer is no. Despite the large 
number of trials, the median number of patients per 
trial was only 78 (IQR 44·0–210·5) and the median 
duration only 1·4 months (IQR 0·9–2·8).4 These 
small numbers explain why the number of events in 
subgroup analyses was low for some of the outcomes. 
These outcomes included rare complications such 
as complicated ulcer disease in non-NSAID users, 
but also events such as further bleeding, blood 
transfusion, and need for endoscopic and surgical 
intervention when analysed by drug class. The very 
short, 3-day median duration of the acute upper 
gastrointestinal bleeding trials probably also influenced 
the results. Furthermore, the analyses did not allow 
firm conclusions to be reached on the effect of 
high-dose PPIs when given orally or intravenously in 
patients with bleeding ulcers. Although initial studies 
focused on high-dose continuous intravenous therapy, 
recent data suggest that intermittent intravenous 
or frequent oral dosing are similarly effective.8,9 The 
latest update of the Asia-Pacific guideline on upper 
gastrointestinal bleeding concluded that high-dose 
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Although there have been major improvements in 
the management of patients undergoing colorectal 
surgery, particularly with the introduction of 
enhanced recovery after surgery (ERAS) pathways 
and laparoscopic surgery, prolonged postoperative 
ileus remains one of the most common complications 
experienced by these patients. Well conducted, 
prospective clinical studies with clear definitions have 
consistently identified postoperative ileus in more than 
20% of patients after colorectal resection.1,2 The cause 
of postoperative ileus is multifactorial and includes 
trauma to both the abdominal wall and the bowel 
itself, activation of inflammatory pathways, fluid 
and electrolyte disturbances, and use of medications 
that alter bowel motility. We desperately need new 
preventative and therapeutic interventions in this 
perplexing field.
In a systematic review and meta-analysis3 of 
13 randomised controlled trials with almost 
1200 patients, early enteral feeding was compared 
with standard postoperative feeding in intestinal 
surgery. A significant reduction in mortality associated 
with feeding within 24 h of surgery was reported. 
However, the reductions in pneumonia, anastomotic 
leakage, and wound infection were not statistically 
significant. Lubbers and colleagues4 proposed 
a possible mechanism whereby early feeding of 
lipid-rich formula might have an effect on the motility 
of the intestine via a cholecystokinin-induced indirect 
stimulation of the vagus nerve. In a single-centre 
randomised controlled trial of 123 patients with 
rectal cancer, Boelens and colleagues5 compared early 
enteral tube feeding with parenteral nutrition both 
starting 8 h after completion of surgery. The findings 
When should feeding begin in patients undergoing 
colorectal surgery?
oral PPIs (defined as ≥80 mg daily) can be used to 
prevent rebleeding (unpublished data), albeit with the 
warning that available studies were relatively small 
and underpowered. The optimum method of dosing 
requires further study. 
In conclusion, the thorough meta-analysis by Scally 
and colleagues provides relevant information for 
many clinicians. It confirms that gastroprotection, 
in particular by means of PPIs, is associated with a 
roughly five times reduced risk of ulcer incidence 
as well as ulcer bleeds when compared with no 
protection, and a five times improvement in ulcer 
healing. It also points to areas that require further 
study, in particular the need to understand whether 
oral and intravenous PPIs are similarly effective in 
patients with bleeding ulcers to prevent rebleeding 
and to reduce the need for intervention including 
endoscopic treatment, transfusion, surgery, and 
prolonged admission. 
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